Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-03-05

FDA Approved: RISPERIDONE — Supplemental Application (Chartwell RX, LLC)

View source ↗

Summary

FDA approved a supplemental application for risperidone from Chartwell RX, LLC, authorizing the generic product under the approved label.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • RISPERIDONE (RISPERIDONE)

Snippet

SUPPL AP for RISPERIDONE (RISPERIDONE)